Sichuan: price and supply of four kinds of drugs will be monitored

On December 30, Sichuan Medical equipment bidding and purchasing service center put up the notice on the investigation of the production cost of drugs with abnormal price changes (hereinafter referred to as the notice), which made specific arrangements for the investigation of the production cost of drugs with abnormal price changes implemented in the province from now on The notice confirms that the production cost of four kinds of drugs will be included in the scope of investigation: first, the drugs with abnormal price changes required by the State Medical Security Bureau to carry out the production cost investigation; second, the drugs for which the manufacturer applies for online listing in Sichuan and requires to increase the online price; third, the drugs with abnormal price increase or frequency and large price difference between regions; Fourth, drugs with large price differences of the same variety, significantly higher prices in circulation than the reasonable level and insufficient competition The original text of the circular is as follows: all drug manufacturers concerned: In order to grasp the situation of drug production cost, analyze the reasons for the abnormal changes of drug price, scientifically and reasonably respond to the abnormal changes of drug price, and guide the reasonable formation of drug price, according to the opinions of the general office of the State Council on further improving the work of supply and price stabilization of drugs in short supply (GBF [2019] No 47), the opinions of the State Medical Insurance Bureau on doing a good job of current drug price management (Guo Baofa [2019] No 67) and notice on monitoring abnormal changes in drug prices and supplies (Medical Insurance Office [2019] No 30) stipulate that with the consent of provincial medical insurance bureau, Sichuan Medical equipment bidding and purchasing service center (hereinafter referred to as "provincial medical equipment bidding and purchasing center") decides to carry out the investigation of production costs of drugs with abnormal changes in prices in Sichuan Province The relevant matters are hereby notified as follows: 1 Scope of investigation The scope of drug production cost investigation: first, the drugs with abnormal price changes required by the State Medical Security Bureau to carry out production cost investigation; second, the drugs with abnormal price increase or abnormal frequency and large price difference between regions; fourth, the drugs with large price difference of the same variety and obvious price increase in circulation link are beyond the agreement Drugs with inadequate management and competition 2、 The investigation and organization of drug production cost investigation organized by Sichuan Medical Security Bureau shall be implemented by Sichuan Medical equipment bidding and purchasing service center 3、 Investigation contents the investigation of the production cost of domestic drugs includes the production cost of drugs and the related production, operation, finance, product flow and price The investigation of import cost of imported drugs includes import cost and related operation, finance, product flow and price 4、 Investigation method: the investigation of drug production cost is mainly in written form, and field investigation is adopted when necessary For the on-the-spot investigation of drug manufacturing enterprises and import enterprises in the province, the provincial drug recruitment and acquisition center shall organize personnel to conduct on-the-spot investigation in the enterprises For the field investigation of the production enterprises and import enterprises outside the province, the enterprise shall submit the field investigation report of the drug production cost approved by the local provincial medical security department to the provincial drug recruitment and acquisition center In case of the following circumstances, field investigation shall be carried out: (1) the written investigation data are insufficient to meet the needs of analyzing and investigating drug price issues; （2） The investigation unit fails to submit the materials according to the specified requirements and time limit or the submitted materials are incomplete and inaccurate; (3) the drug market price fluctuates greatly; (4) the masses write letters to reflect the concentrated drug price problems; (5) the inquiry and interview can not explain the reasons for the price increase or refuse to make the price adjustment according to the requirements; （6） Other situations requiring on-the-spot investigation; V specific requirements (I) drugs with abnormal price changes required by the state health insurance bureau to carry out production cost investigation will be determined according to the monthly price monitoring and the specific provisions of the state health insurance bureau (medical insurance Ban Fa [2019] No 30) document The relevant drug production and marketing enterprises shall fill in the data of drug production cost according to the requirements, and the provincial drug and equipment bidding and purchasing center shall summarize the investigation results and report them to the State Medical Security Bureau and the Provincial Medical Security Bureau （2） For the investigation of drug production cost that the manufacturer requires to increase the price of drug on the Internet, the manufacturer shall submit the data of drug production cost together with the application materials of drug on the Internet as an important basis for analyzing the rationality of price increase （3） According to the results of drug price monitoring, the provincial pharmaceutical machinery bidding and purchasing center shall irregularly put forward the list of drugs requiring production cost investigation and organize the implementation of production cost adjustment It can be used as the basis for analyzing drug price and taking reasonable countermeasures （4） All relevant pharmaceutical manufacturers and imported pharmaceutical enterprises shall truthfully, accurately and comprehensively fill in the production cost survey data and provide relevant supporting materials For the enterprises that do not report or make a false report, when examining their online sales qualification, they will deal with it by making a false report, concealing the report or not reporting the relevant information （5） In order to enhance the transparency of the drug production cost investigation, we will establish the enterprise credit file according to the drug production cost investigation and regularly issue the enterprise credit announcement The contents of the announcement include: the name of the manufacturer, the name of the drug variety, the historical transaction price, the credit rating, etc 6、 This notice shall be implemented as of the date of promulgation Sichuan Medical equipment bidding and purchasing service center December 23, 2019